- Home
- LFT vs OTLK Comparison
LFT vs OTLK Comparison
Compare LFT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- OTLK
- Stock Information
- Founded
- LFT 2012
- OTLK 2010
- Country
- LFT United States
- OTLK United States
- Employees
- LFT N/A
- OTLK N/A
- Industry
- LFT Real Estate Investment Trusts
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFT Real Estate
- OTLK Health Care
- Exchange
- LFT Nasdaq
- OTLK Nasdaq
- Market Cap
- LFT 127.0M
- OTLK 121.8M
- IPO Year
- LFT N/A
- OTLK 2016
- Fundamental
- Price
- LFT $2.57
- OTLK $5.03
- Analyst Decision
- LFT Buy
- OTLK Strong Buy
- Analyst Count
- LFT 3
- OTLK 7
- Target Price
- LFT $2.50
- OTLK $48.20
- AVG Volume (30 Days)
- LFT 80.3K
- OTLK 243.0K
- Earning Date
- LFT 11-12-2024
- OTLK 12-20-2024
- Dividend Yield
- LFT 12.45%
- OTLK N/A
- EPS Growth
- LFT 52.72
- OTLK N/A
- EPS
- LFT 0.35
- OTLK N/A
- Revenue
- LFT $36,400,239.00
- OTLK N/A
- Revenue This Year
- LFT N/A
- OTLK N/A
- Revenue Next Year
- LFT N/A
- OTLK N/A
- P/E Ratio
- LFT $7.41
- OTLK N/A
- Revenue Growth
- LFT 25.67
- OTLK N/A
- 52 Week Low
- LFT $2.03
- OTLK $4.61
- 52 Week High
- LFT $2.75
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- LFT 54.92
- OTLK 35.70
- Support Level
- LFT $2.32
- OTLK $5.03
- Resistance Level
- LFT $2.50
- OTLK $5.44
- Average True Range (ATR)
- LFT 0.09
- OTLK 0.37
- MACD
- LFT 0.01
- OTLK -0.12
- Stochastic Oscillator
- LFT 90.29
- OTLK 2.01
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.